Answers are grounded in this paper and cite their sources.
Herein, dasatinib (DASA) and heme oxygenase-1 (HO-1) inhibitor codrugs were designed and synthesized. Derivatization of DASA was performed by preserving the structural features essential for target inhibition and was rationally guided by molecular modelling studies. Two out of three synthesized codrugs showed the ability to inhibit HO-1 activity in a low micromolar range (i.e., 2.12 and 1.00 μM for TC7 and TC8, respectively), while all derivatives retained a significant capability of inhibiting the cSRC tyrosine kinase with sub-micromolar potency (i.e., 0.0023–0.0255 μM). Of note, derivative TC7 exhibited significant in vitro antiproliferative activity against U87MG glioblastoma cells, likely mediated by HO inhibition and accompanied by a ∼1.5-fold increase in intracellular ROS levels compared with the control. Also, assessment of the most promising codrug, TC7, revealed high chemical and enzymatic stability (t1/2 >24 h). While additional optimization will be required to further improve its drug-like profile, TC7 emerged as the most promising compound evaluated in this study and represents a suitable starting point for future development. Collectively, these results serve as a proof of concept supporting a potential new codrugs strategy combining HO-1 and cSRC inhibition for glioblastoma therapy.
No takes yet. Share an insight, caveat, or question.
Pittalà et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: